Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,849 total articles
Texas Community Bancshares (TCBS) is a sub-$100M market-cap bank showing consecutive record quarters, margin improvement and a rising dividend. At roughly $17.68 per share, it trades below book and at a mid-teens P/E. This trade aims to capture a move back toward the $20 area over a mid-term 45 trading-day horizon while limiting downside with a dis…
Delta has a unique offset in the airline group: an integrated refinery that supplies jet fuel to its operations and can generate positive margin when the jet fuel complex widens. With shares near $92.77 and technical momentum intact, a measured long makes sense as a mid-term swing (45 trading days) to capture re-rating if refinery economics and sum…
PBF Energy looks like a directional, mid-term long: the company is a domestic refiner with leverage to widening crack spreads driven by disruptions in the Strait of Hormuz. The balance sheet is intact, valuation is reasonable on EV/EBITDA, and the stock has room to re-test its recent 52-week high. Trade plan below with entry, stop and target — cali…
MACOM (MTSI) combines steady defense/radar exposure with a rapidly growing data-center optics business. With 22.5% reported sales growth and management moves to secure epitaxial supply, the risk/reward today favors a measured long. Entry $273.51, stop $235.00, target $360.00 over a 180-trading-day position—play the structural AI buildout while resp…
XP Inc. combines a technology-driven wealth platform with advisory and product distribution, and recent moves into tokenization plus healthy profitability give the stock asymmetric upside from a low valuation. We outline a mid-term swing trade at $16.97 with a $21 target and a $15 stop, backed by improving fundamentals and technicals but balanced b…
Wix rallied sharply after management flagged structural profitability improvements from its Base44 AI initiative. That news is constructive for margins, but the stock has already run hard ($56.84 to $67.03 intraday) into heavy short interest, pending securities litigation, and an earnings history of operating-cost surprises. We recommend a tactical…
Grab is showing tangible GMV and revenue acceleration with profitability metrics improving, yet the stock remains below prior highs and cheap enough on a recovery multiple to offer upside for a disciplined swing trade. We outline an actionable plan with a clear stop and target, and the key catalysts and risks that should move the stock over the nex…
Zebra Technologies is registering renewed momentum as customers rush to deploy inventory-tracking, barcode and RFID systems tied to AI-driven frontline workflows. With a market cap near $17.6B, $836M in free cash flow and recent bullish guidance, the stock looks set for further upside toward $460 over the next 180 trading days, provided margins rec…
Rolls-Royce (RYCEY) looks buyable after Q2 as the market prices in nuclear SMR funding, steady civil-aero aftermarket demand and constructive technicals. The stock trades near a 52-week high at $20.62, backed by bullish MACD and EMAs above major moving averages. I outline five reasons to own, catalysts that could push shares higher, explicit entry/…
Apollo's shares jumped after a reassuring near-term update and the market's shift toward alternative income. With a market cap near $81B, attractive dividend yield, and tailwinds from the potential expansion of private credit into 401(k) plans, the risk/reward favors a tactical long. This trade lays out entry, stop, targets and the events that coul…
ClearPoint Neuro is a small-cap medical device company focused on MRI-guided neurosurgical systems. Recent commercial rollouts, clinical partnerships and a growing MRI-guided ablation market create a structural growth opportunity. The stock is down from its 52-week high and trading below near-term moving averages, offering a tradeable long with def…
EverQuote is a profitable, cash-generative insurance marketplace trading at a bargain multiple. With the balance sheet flexibility to ramp variable marketing dollars and proven unit economics, this trade targets a re-acceleration in lead volume and revenue over the next 45 trading days. Entry at $23.86, stop $21.00, target $30.00.
Mitsubishi UFJ Financial (MUFG) is attractively priced at $21.83 with a market cap of $262.7B, P/E of 14.6 and PB of 1.81. Recent macro signals from the Bank of Japan and continued earnings momentum position MUFG to benefit from a higher-for-longer rates regime. This trade idea outlines a tactical long: entry $21.83, stop $20.50, target $24.00 — a …
Enbridge (ENB) owns critical North American pipeline infrastructure with sticky fee-based cash flow, a 5.1% yield and manageable payout coverage. Technical weakness presents a buyable entry for a mid-term swing trade with defined risk, targeting a retest of the 52-week highs while collecting the upcoming dividend.
Apple plunged after flagging rising memory costs and conservative guidance, but the company still prints cash, shows strong demand, and sits at a lower risk entry for a mid-term rebound as memory markets normalize and services recover. This is a tactical long with a clear entry, stop and target for a 45-trading-day trade window.
Bombardier Inc A (BDRAF) is actionable here after a clean move above key moving averages, constructive momentum indicators and elevated days-to-cover that create asymmetric upside. Entry at current levels targets a return to obvious round-number resistance while keeping a tight stop under the 50-day moving average.
XPLR Infrastructure is being valued as a stable yieldco but its project funding needs, fragile covenant profile, and a likely distribution reset create an asymmetric short opportunity. Enter short at $8.20, stop at $11.00, target $4.80 over a mid-term 45 trading day horizon.
OPKO Health is a beaten-down, yet operationally active biopharma and diagnostics company trading below $1B market cap. With partnerships advancing oral peptide programs with Entera Bio and ModeX's multispecific antibody effort gaining scientific heft, a successful clinical/data cadence over the next 6-12 months could push the stock materially highe…
Okta reported a clean beat on 05/29/2026, produced meaningful free cash flow and raised guidance. The market is beginning to re-rate the identity-security leader; this trade targets that re-rating over the next 45 trading days while protecting against momentum fade and valuation risk.
Allied Gold's price collapse following the termination of Zijin's takeover bid looks excessive. The company remains a producing gold miner with operating optionality and near-term catalysts that can re-anchor the stock. This is a tactical long recommendation with defined entry, stop and target for a long-term (180 trading days) recovery play.
Alibaba sits at the intersection of cloud compute, vast commerce data, and logistics — the three inputs most investors overlook when valuing AI winners. With a $323B market cap, a PE around 19 and visible operational hookups across industries, a measured long bias captures upside if regulatory/legal overhangs stabilize.
SoFi reported strong Q2 top-line growth and membership metrics but held adjusted EBITDA guidance, handing sellers an excuse. The shares trade at a premium to current cash flow metrics; momentum technicals and heavy short interest set up a tactical long if management signals a clearer path to higher profitability. This trade idea targets a mid-term …
I increased my Tesla position by 50% today at $325.00 because recent weakness has pulled forward uncertainty into the price while leaving long-dated upside intact. Q2 weakness and a temporary free-cash-flow hole have reset expectations; the company still has $1.28T market cap scale, meaningful positive trailing free cash flow, and early robotaxi so…
BlackRock Health Sciences Term Trust (BMEZ) offers a compelling mix of high current cash distribution, modest momentum, and favorable technical setup as institutional flows rotate into healthcare. We recommend a tactical long with an entry near the market price, a protective stop below the recent range, and two upside targets that capture a re-test…
Apple remains a cash-generative giant, but at $306.30 the stock is priced for near-flawless execution. Valuation (PE ~35), weakening technicals and rising component costs create an asymmetric trade: short AAPL at $306.30, stop loss $319.00, initial target $270.00 (mid-term, 45 trading days). Risk is material; position size accordingly.
